Bifidobacterium spp. and their metabolite lactate protect against acute pancreatitis via inhibition of pancreatic and systemic inflammatory responses. (31st December 2022)

• Record Type: Journal Article
• Authors: Li, Han; Xie, Jinyan; Guo, Xiuliu; Yang, Guilian; Cai, Bin; Liu, Jingtianyi; Yue, Mengjia; Tang, Yixin; Wang, Gan; Chen, Shuxian; Guo, Jialin; Qi, Xuchen; Wang, Donghai; Zheng, Huijun; Liu, Wei; Yu, Hong; Wang, Chunfeng; Zhu, Shu Jeffrey; Guo, Feng
• Is Part Of: Gut microbes. Volume 14:Isuse 1(2022)
• Publication Date: 2022-12-31
• Subjects: Bifidobacterium -- microbial metabolite -- lactate -- macrophages -- pancreatic and systemic inflammation -- immunomodulation; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2022.2127456
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTRACT: Severe acute pancreatitis (SAP) is a critical illness characterized by a severe systemic inflammatory response resulting in persistent multiple organ failure and sepsis. The intestinal microbiome is increasingly appreciated to play a crucial role in modulation of AP disease outcome, but limited information is available about the identity and mechanism of action for specific commensal bacteria involved in AP-associated inflammation. Here we show that Bifidobacteria, particularly B. animalis, can protect against AP by regulating pancreatic and systemic inflammation in germ-free (GF) and oral antibiotic-treated (Abx) mouse models. Colonization by B. animalis and administration of its metabolite lactate protected Abx and GF mice from AP by reducing serum amylase concentration, ameliorating pancreatic lesions and improving survival rate after retrograde injection of sodium taurocholate. B. animalis relieved macrophage-associated local and systemic inflammation of AP in a TLR4/MyD88- and NLRP3/Caspase1-dependent manner through its metabolite lactate. Supporting our findings from the mouse study, clinical AP patients exhibited a decreased fecal abundance of Bifidobacteria that was inversely correlated with the severity of systemic inflammatory responses. These results may shed light on the heterogeneity of clinical outcomes and drive the development of more efficacious therapeutic interventions for AP, and potentially for other inflammatory disorders.